SCHEMBL3475619

SCHEMBL3475619

N#Cc1ccccc1NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
HSD17B10 Q99714 2/20 1.00
HPGD P15428 2/20 1.00
TSHR P16473 2/20 1.00
PRKACA P17612 1/20 0.57
CDK8 P49336 1/20 0.57
CLK2 P49760 1/20 0.57
GSK3A P49840 1/20 0.57
GSK3B P49841 1/20 0.57
CDK9 P50750 1/20 0.57
CDK5 Q00535 1/20 0.57
PRKCQ Q04759 1/20 0.57
ROCK1 Q13464 1/20 0.57
DYRK1A Q13627 1/20 0.57
LRRK2 Q5S007 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
DYRK1B Q9Y463 1/20 0.57
HTR2A P28223 1/20 0.52
HTR6 P50406 1/20 0.52
CYP19A1 P11511 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873028 0.86 KDM4E (0.75) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL27545525 0.86 KDM4E (0.75) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL10330188 0.86 KDM4E (0.75) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL29456651 0.84 KDM4E (0.73) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL31519277 0.82 TSHR (0.69) KDM4EHSD17B10HPGDTSHRCYP19A1
SCHEMBL11468954 0.81 HSD17B10 (0.68) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL12497079 0.80 KDM4E (0.66) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL30607653 0.80 TSHR (0.66) KDM4EHSD17B10HPGDTSHRPRKACA
SCHEMBL4571036 0.79 HSD17B10 (0.71) KDM4EHSD17B10HPGDTSHRMEN1
SCHEMBL30464743 0.79 HSD17B10 (0.71) KDM4EHSD17B10HPGDTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110313158-A1 Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-12-22 US claimed
WO-2010097815-A2 A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-09-02 WO claimed
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2024-06-13 US disclosed
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2022-12-29 US disclosed
CN-110003172-B Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators 同步制药公司 2022-04-01 CN disclosed
EP-3939971-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. (US) 2022-01-19 EP disclosed
EP-3326715-B1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE CE PHARM CO LTD (CN) 2021-09-15 EP disclosed
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2021-06-10 US disclosed
EP-3129366-B1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYNCHRONICITY PHARMA INC (US) 2021-06-09 EP disclosed
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. (US) 2020-09-01 US disclosed
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2019-08-08 US disclosed
US-20090149659-A1 1-ALKYL-3-AMINOINDAZOLES ALCON, INC. (CH) 2009-06-11 US disclosed
CN-100361977-C 1-alkyl-3-aminoindazoles ALCON INC (CH) 2008-01-16 CN disclosed
EP-1578729-A4 1-ALKYL-3-AMINOINDAZOLES ALCON INC (CH) 2007-08-29 EP disclosed
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses GENFIT (FR) 2006-04-13 US disclosed
WO-2006035157-A2 SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS GENFIT (FR) 2006-04-06 WO disclosed
US-20060052613-A1 1-alkyl-3-aminoindazoles ALCON, INC. (CH) 2006-03-09 US disclosed
CN-1732157-A 1-alkyl-3-aminoindazoles ALCON INC (CH) 2006-02-08 CN disclosed
EP-1578729-A1 1-ALKYL-3-AMINOINDAZOLES Alcon, Inc. (CH) 2005-09-28 EP disclosed
WO-2004058725-A1 1-ALKYL-3-AMINOINDAZOLES ALCON, INC. (CH) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS KDM4E 1254/4885HSD17B10 1044/4885HPGD 2050/4885
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses AADAC, NAT1, PARN KDM4E 2470/4885HSD17B10 3633/4885HPGD 817/4885
US-20060052613-A1 1-alkyl-3-aminoindazoles NAT1, AADAC, CYP1B1 KDM4E 2238/4885HSD17B10 961/4885HPGD 136/4885
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS KDM4E 1254/4885HSD17B10 1044/4885HPGD 2050/4885
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators CRY1, CRY2, HCCS KDM4E 1254/4885HSD17B10 1044/4885HPGD 2050/4885
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS KDM4E 1254/4885HSD17B10 1044/4885HPGD 2050/4885
US-20110313158-A1 Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines HCN2, RAC2, HCN1 KDM4E 2112/4885HSD17B10 1800/4885HPGD 2141/4885
US-20090149659-A1 1-ALKYL-3-AMINOINDAZOLES NAT1, AADAC, CYP1B1 KDM4E 2238/4885HSD17B10 961/4885HPGD 136/4885
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS KDM4E 1254/4885HSD17B10 1044/4885HPGD 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.